Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) Interactions
There are 321 drugs known to interact with Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) (sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)). Of the total drug interactions, 1 is major, 317 are moderate, and 3 are minor.
- View all 321 medications that may interact with Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308)
Most frequently checked interactions
View interaction reports for Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) (sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)) and the medicines listed below.
- Afluria Quadrivalent (influenza virus vaccine, inactivated)
- aluminum hydroxide / magnesium carbonate
- Arexvy (rsv vaccine pref3, recombinant)
- atorvastatin
- boron
- calcium carbonate
- calcium citrate
- calcium / vitamin d
- carvedilol
- diphtheria toxoid / pertussis, acellular / tetanus toxoid
- Evamist (estradiol)
- Evening Primrose Oil (evening primrose)
- Excedrin (acetaminophen / aspirin / caffeine)
- FluLaval Quadrivalent (influenza virus vaccine, inactivated)
- Fluzone Quadrivalent (influenza virus vaccine, inactivated)
- Fosamax (alendronate)
- gabapentin
- Gaviscon Extra Strength (aluminum hydroxide / magnesium carbonate)
- hepatitis a adult vaccine
- hepatitis b adult vaccine
- ibuprofen
- latanoprost ophthalmic
- leuprolide
- lisinopril
- magnesium oxide
- Paxlovid (nirmatrelvir / ritonavir)
- Pfizer-BioNTech COVID-19 (12y+) Bivalent Booster Vaccine PF (sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine)
- Reclast (zoledronic acid)
- Refresh PM (ocular lubricant ophthalmic)
- sars-cov-2 mrna (tozinameran) vaccine
More about Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) (sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308))
- Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- Drug class: viral vaccines
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.